Novo's drug, CagriSema, didn't achieve its key goal of demonstrating non-inferiority on weight loss when compared to Eli Lilly's rival drug tirzepatide. The stock plummeted on Monday, hitting its ...
Novo Nordisk’s experimental weekly shot CagriSema was shown to lead to less dramatic weight loss compared to rival Lilly’s Tirzepatide, the drug behind Zepbound and Mounjaro, in an 84-week trial, Novo ...
CagriSema shows 23% weight loss versus 25.5% for Zepbound Novo's shares drop 15% Lilly's shares rise 4% in US pre-market trading Outcome is 'worst-case scenario' for Novo, investor says Few analysts ...
The weight-loss drugs that kicked off America's GLP-1 craze are about to get a lot less expensive, though only certain customers will notice the savings. Novo Nordisk said it will slash list prices of ...
Novo Nordisk’s GLP-1/amylin combo has failed to beat Eli Lilly’s obesity blockbuster Zepbound in a phase 3 weight loss study, further denting the Danish pharma’s attempts to reclaim its obesity crown.
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — Novo Nordisk’s next-generation weight loss drug CagriSema, one ...
Novo Nordisk (NVO) shares fell over 15% on Monday after the company’s next-generation obesity drug CagriSema delivered less weight loss than Eli Lilly’s (LLY) competing treatment in a phase 3 trial, ...
Novo Nordisk just admitted that its CagriSema weight loss drug isn't obviously better than Zepbound. This is a win for Eli Lilly, and a loss for Novo Nordisk. That sounds like pretty good news, but ...
Novo Nordisk on Tuesday said it plans to slash the monthly list prices of its popular obesity and diabetes drugs in the U.S. by up to 50% starting in 2027. The move aims to make the treatments more ...
Novo Nordisk (NVO) is planning to sell its obesity drugs on the telehealth platform run by Hims & Hers Health (HIMS) as part of a partnership between the two firms, Bloomberg reported, citing a person ...
Novo hoped its next obesity drug would close the gap. Instead, it may have widened Eli Lilly’s lead.
LONDON, Feb 24 (Reuters) - With U.S. arch rival Eli Lilly (LLY.N), opens new tab streaking away on weight-loss prescriptions and valuation, the last thing Novo Nordisk (NOVOb.CO), opens new tab needed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results